Cipla, a global pharmaceutical company announces that it has been awarded USD 188.95 million of Global Fund ARV Tender and has been selected as a ‘Panel Supplier’ for a supplier partnership agreement. The contract is effective from January 01, 2015 and will run for a period of three years. The supplies will begin from Q4 FY 2015.
Subhanu Saxena, managing director & global chief executive officer, Cipla Limited says, “We are extremely proud to have won this tender from Global Fund. Cipla has been committed to the cause of HIV/AIDS for over two decades and this tender offers us a great opportunity to make HIV/AIDS treatment accessible to more than 140 countries through Global Fund.
Cipla has a long-term association with Global Fund since 2002. Last year, Cipla has been one of the suppliers who has been awarded with a long-term contract for supplying anti-malarial drugs.
The anti-retrovirals drugs will be manufactured in Cipla’s state-of-the-art manufacturing facilities in India, which has been approved by various international regulatory agencies.
Cipla, a global pharmaceutical company, uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Cipla’s portfolio includes over 1500 products in various therapeutic categories with one quality standard globally. Cipla’s turnover in 2013/14 was 1.7 billion USD.
Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.
Cipla’s research and development focusses on developing innovative products and drug delivery systems and has given India and the world many ‘firsts’ for instance Triomune. In a tightly regulated environment, the company’s manufacturing facilities have approvals from all the main regulators including US FDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.